Working… Menu

Safety Study for Treatment of Wet Macular Degeneration Using the TheraSight(TM) Ocular Brachytherapy System

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00100087
Recruitment Status : Unknown
Verified January 2005 by Theragenics Corporation.
Recruitment status was:  Recruiting
First Posted : December 23, 2004
Last Update Posted : June 24, 2005
Information provided by:
Theragenics Corporation

Brief Summary:
The study will investigate the safety and feasibility of using the TheraSight(TM) Brachytherapy System for treatment of wet age-related macular degeneration (AMD).

Condition or disease Intervention/treatment Phase
Macular Degeneration Choroidal Neovascularization Device: Ocular Brachytherapy Phase 1 Phase 2

Detailed Description:
This is a multi-center randomized study of three doses of radiation (assigned 1:1:1) delivered by the TheraSight(TM) Brachytherapy System in participants with choroidal neovascularization (CNV) secondary to wet (exudative) AMD. Each participant receives a single dose of radiation delivered by one-time only brachytherapy. Participants are followed for three years after the radiation treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Safety and Feasibility Study of the TheraSight(TM) Ocular Brachytherapy System for Treatment of Age-Related Macular Degeneration
Study Start Date : October 2004

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Incidence of serious adverse events 30 to 270 days after treatment

Secondary Outcome Measures :
  1. Serious adverse events occurring 9 months to 3 years after treatment
  2. Reported adverse events occurring at any time after treatment
  3. Feasibility of device use based on physician interviews and ultrasonography
  4. Observation of retinal and angiographic appearance of CNV lesion and best-corrected visual acuity

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 50 years or older.
  • Active primary or recurrent subfoveal CNV secondary to AMD with minimally classic or occult lesion, where an active lesion is defined as one or more of the following:

    a) An increase > 10% in lesion size (greatest linear dimension) on screening fluorescein angiography compared to previous fluorescein angiography no more than 180 days preceding screening visit

    • b) Subretinal hemorrhage associated with CNV within 90 days of screening visit.
    • c) Visual acuity loss > 1 Snellen line in screening visual acuity compared to previous visual acuity no more than 180 days preceding screening
  • Lesion < 6 mm greatest linear dimension (GLD)
  • Submacular blood must comprise less than 75% of the total lesion
  • Subretinal fibrosis must comprise less than 25% of the total lesion
  • Study eye best-corrected vision of 20/100 or poorer measured on an ETDRS chart (< 48 letters correct)
  • Fellow eye best-corrected vision that is at least one line better on an ETDRS chart than the best-corrected vision of the study eye
  • HbA1c < 6%
  • Read and signed informed consent

Exclusion Criteria:

  • Prior AMD therapy treatment, including but not limited to laser and photodynamic therapy.
  • Current or planned participation in the next 180 days in other experimental trials involving treatment of neovascular AMD in the study eye, ocular devices, or trials involving treatment for ocular conditions other than AMD.
  • Prior ophthalmic surgery for the study eye other than cataract extraction and/or capsulotomy. A minimum interval of 180 days must elapse between cataract extraction or capsulotomy and study enrollment.
  • Likely need for cataract surgery in study eye during the 180 days following TheraSight(TM) System treatment.
  • Presence of other eye diseases that could compromise visual acuity in the study eye or that, in the clinical judgment of the evaluating study ophthalmologist, might create special risk for the study participant.
  • CNV due to other causes such as ocular histoplasmosis or pathologic myopia.
  • Endstage fibrotic disciform lesions.
  • Diabetes requiring diet modification, or medication, or insulin.
  • Current history of malignancy (except participants having basal cell carcinoma that was treated successfully, or other malignancy operated on or treated and in remission for five years prior to inclusion in the trial).
  • Hypertensive retinopathy.
  • Major cardiovascular or cerebrovascular event within the last year; examples include congestive heart failure, myocardial infarction, and stroke.
  • Inability to complete follow-up.
  • Allergy to fluorescein dye.
  • Previous radiation to the study eye.
  • Pregnancy at time of surgical procedure.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00100087

Layout table for location contacts
Contact: Theragenics Corporation 1-877-960-1234

Layout table for location information
United States, Georgia
Theragenics Clinical Site Recruiting
Atlanta, Georgia, United States
Theragenics Clinical Site Recruiting
Augusta, Georgia, United States
United States, Indiana
Theragenics Clinical Site Recruiting
Indianapolis, Indiana, United States
United States, Massachusetts
Theragenics Clinical Site Recruiting
Boston, Massachusetts, United States
United States, New Jersey
Theragenics Clinical Site Recruiting
Newark, New Jersey, United States
United States, North Carolina
Theragenics Clinical Site Recruiting
Raleigh / Durham, North Carolina, United States
Sponsors and Collaborators
Theragenics Corporation

Layout table for additonal information Identifier: NCT00100087     History of Changes
Other Study ID Numbers: NPD-07-01
First Posted: December 23, 2004    Key Record Dates
Last Update Posted: June 24, 2005
Last Verified: January 2005
Keywords provided by Theragenics Corporation:
macular degeneration
choroidal neovascularization
retinal degeneration
retinal diseases
Additional relevant MeSH terms:
Layout table for MeSH terms
Macular Degeneration
Choroidal Neovascularization
Neovascularization, Pathologic
Retinal Degeneration
Retinal Diseases
Eye Diseases
Pathologic Processes
Choroid Diseases
Uveal Diseases